BANGALORE –  Dr. Reddy's Laboratories Ltd. (500124.BY) said Friday that it has resolved an issue involving objections from the U.S. Food and Drug Administration over the company's promotion of a copy of GlaxoSmithKline PLC's (GSK) anticlotting Arixtra injection.

The issue relates to the FDA pulling up Dr. Reddy's for not highlighting an important risk information on a promotional website for fondaprinux sodium injections--the generic version of Arixtra.

Dr. Reddy's said in a statement that it has addressed all matters raised by the FDA's division for professional promotion and that the U.S. drug regulator has informed the company the issue is now closed.

Copyright © 2012 Dow Jones Newswires